Rankings
▼
Calendar
VCYT Q4 2025 Earnings — Veracyte, Inc. Revenue & Financial Results | Market Cap Arena
VCYT
Veracyte, Inc.
$3B
Q4 2025 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$141M
+18.5% YoY
Gross Profit
$105M
74.4% margin
Operating Income
$26M
18.4% margin
Net Income
$41M
29.3% margin
EPS (Diluted)
$0.50
QoQ Revenue Growth
+6.6%
Cash Flow
Operating Cash Flow
$53M
Free Cash Flow
$48M
Stock-Based Comp.
$11M
Balance Sheet
Total Assets
$1.4B
Total Liabilities
$96M
Stockholders' Equity
$1.3B
Cash & Equivalents
$363M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$141M
$119M
+18.5%
Gross Profit
$105M
$79M
+32.9%
Operating Income
$26M
$4M
+521.3%
Net Income
$41M
$5M
+704.8%
Revenue Segments
Testing
$136M
97%
Product
$4M
3%
Biopharmaceutical And Other
$686,000
0%
← FY 2025
All Quarters